UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Stock Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 41.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 47,899 shares of the specialty pharmaceutical company's stock after buying an additional 13,948 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.23% of ANI Pharmaceuticals worth $2,648,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. US Bancorp DE raised its stake in shares of ANI Pharmaceuticals by 842.9% during the 4th quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company's stock valued at $33,000 after purchasing an additional 531 shares during the period. KBC Group NV boosted its stake in ANI Pharmaceuticals by 89.2% in the 4th quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company's stock worth $70,000 after purchasing an additional 600 shares during the period. KLP Kapitalforvaltning AS purchased a new position in ANI Pharmaceuticals during the 4th quarter valued at about $166,000. Rafferty Asset Management LLC bought a new stake in shares of ANI Pharmaceuticals during the fourth quarter valued at about $200,000. Finally, Bridgefront Capital LLC purchased a new stake in shares of ANI Pharmaceuticals in the fourth quarter worth about $204,000. Institutional investors own 76.05% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on ANIP. Wall Street Zen cut shares of ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Thursday, April 24th. HC Wainwright restated a "buy" rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a research report on Monday, March 17th. Jefferies Financial Group assumed coverage on shares of ANI Pharmaceuticals in a research report on Friday, March 14th. They set a "buy" rating and a $80.00 target price for the company. Guggenheim reiterated a "buy" rating and set a $86.00 price objective on shares of ANI Pharmaceuticals in a research report on Monday, May 12th. Finally, JPMorgan Chase & Co. began coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, March 12th. They issued an "overweight" rating and a $85.00 target price on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $80.13.

ANI Pharmaceuticals Trading Down 0.5%

Shares of ANI Pharmaceuticals stock traded down $0.31 during midday trading on Tuesday, reaching $62.87. 262,045 shares of the company's stock traded hands, compared to its average volume of 309,148. The stock has a 50 day moving average of $64.94 and a 200-day moving average of $61.01. ANI Pharmaceuticals, Inc. has a 12 month low of $52.50 and a 12 month high of $77.00. The company has a market cap of $1.36 billion, a PE ratio of -114.31 and a beta of 0.55. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its earnings results on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share for the quarter, beating analysts' consensus estimates of $1.37 by $0.33. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The firm had revenue of $197.12 million for the quarter, compared to analyst estimates of $179.75 million. During the same quarter in the previous year, the firm posted $0.82 EPS. The company's revenue for the quarter was up 43.4% compared to the same quarter last year. As a group, equities analysts expect that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current fiscal year.

Insider Activity at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, SVP Ori Gutwerg sold 881 shares of the stock in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $60.07, for a total value of $52,921.67. Following the transaction, the senior vice president now directly owns 89,897 shares in the company, valued at approximately $5,400,112.79. This trade represents a 0.97% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Meredith Cook sold 400 shares of the business's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $63.33, for a total transaction of $25,332.00. Following the sale, the vice president now directly owns 80,545 shares of the company's stock, valued at approximately $5,100,914.85. The trade was a 0.49% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 5,681 shares of company stock valued at $347,638 in the last three months. Company insiders own 11.10% of the company's stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.